In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and
1016/S0140-6736(04)16616-6 No abstract available Publication
Research Open access Published: 21 December 2006 Comparison of the
Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was
Background: Hypertension and dyslipidemia significantly contribute to
According to the dose-response analyses, mean differences between the LDL cholesterol dose-response slopes of rosuvastatin 10 to 80 mg versus atorvastatin 10 to 80 mg and pravastatin 10 to 40 mg were significant (both p <0
At daily doses of 5–40 mg, rosuvastatin produces mean reductions in plasma LDL cholesterol of 45–63%, statistically greater than those achieved with equivalent Of the 1,925 participants screened, 440 were administered the study drug, with 197 (44
Aim: To evaluate and compare the safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia
Introduction: Ezetimibe/statin combination therapy has been reported to provide additional cardioprotective effects compared to statin monotherapy
We also review the major clinical trials with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other Safety and efficacy of statin therapy
Several large-scale clinical trials have demonstrated the safety and efficacy of statins in reducing cardiovascular events 4 In the rosuvastatin-treated group, the rate of myalgia was 4
As there is limited literature available on the efficacy of statins in Asian populations, the current meta-analysis compared the effects of rosuvastatin and atorvastatin on LDL-C levels in
Methods: This study was a randomized, multicenter, open, parallel phase 4
Rosuvastatin 10 to 40 mg/day caused LDL-cholesterol decreases of 46% to 55%, when all the trials were combined using the generic inverse variance method
At 12 weeks, rosuvastatin 5 and 10 mg reduced LDL-C significantly more than
Objectives: We investigated the efficacy of intensive rosuvastatin therapy plus 7-day dual antiplatelet therapy (DAPT) in reducing stroke recurrence for patients with acute ischemic stroke (AIS) and compared subgroups of patients
The present multicenter, 6-week, randomized, double-blind, parallel-group, clinical trial evaluated the safety and efficacy of ezetimibe (10 mg) added to stable rosuvastatin therapy versus up-titration of rosuvastatin from 5 to 10 mg or from 10 to 20 mg
2147/vhrm